FDA clears subcutaneous Rybrevant Faspro for recurrent head and neck cancer

The Food and Drug Administration granted accelerated approval on 5 November to amivantamab and hyaluronidase-lpuj, the subcutaneous co-formulation marketed as Rybrevant Faspro, for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody [s1][s2]. The label draws one explicit boundary: the drug is not indicated for HPV-associated oropharyngeal squamous cell carcinoma [s1].

That exclusion is the first thing to understand about the approval. Head and neck squamous cancers split into two biologically different diseases. Tumours driven by the human papillomavirus, which tend to arise in the oropharynx, behave and respond differently from those linked to tobacco and alcohol. The trial behind this clearance deliberately left the HPV-associated oropharyngeal group out, so the label follows the evidence and does not extend to them [s1].

What amivantamab is

Amivantamab is a bispecific antibody that targets two receptors at once — EGFR and MET — both of which can drive squamous-cell tumours. It was first approved in lung cancer, where EGFR biology is well mapped. Rybrevant Faspro is the under-the-skin version, co-formulated with hyaluronidase, an enzyme that lets a large volume of antibody spread and absorb from subcutaneous tissue rather than being dripped in through a vein. The head and neck indication is new; the molecule is not.

The evidence

Approval rests on OrigAMI-4 (NCT06385080), a multicentre, open-label, multi-cohort study [s1]. The efficacy analysis covered 102 patients with recurrent or metastatic HNSCC who had already progressed after platinum chemotherapy and a PD-(L)1 inhibitor [s1]. Patients whose tumours were HPV-associated oropharyngeal cancer, identified by p16 testing, were excluded from the study [s1].

The overall response rate — the share of patients whose tumours shrank by a defined amount — was 42% (95% CI 32%, 52%), assessed by blinded independent central review using RECIST v1.1 [s1]. Among those who responded, 56% had a response that lasted at least six months [s1].

Those two numbers should be read together and read plainly. A 42% response rate in a group that has already exhausted chemotherapy and immunotherapy is a real signal in a setting with few options. But a single-arm trial measures what happened to patients given the drug; it has no comparison group, so it cannot say how much of that benefit is attributable to amivantamab rather than to the natural course of the disease or to patient selection. And a response is not the same as living longer: accelerated approval here is built on tumour shrinkage, an endpoint the FDA accepts as reasonably likely to predict benefit, not on demonstrated gains in survival.

Accelerated, which means provisional

This is an accelerated approval [s1]. The pathway lets the agency clear a drug on an endpoint such as response rate, on the understanding that the manufacturer must run a confirmatory trial to show the treatment actually helps patients live longer or better. If that trial fails or is not done, the approval can be withdrawn. Readers should treat the indication as conditional rather than settled — a licence to use the drug now, paired with an obligation to prove its worth later.

How it is given, and its risks

Rybrevant Faspro is given as a weight-based subcutaneous injection every three weeks, on its own, until the disease progresses or side effects become unacceptable [s1]. The subcutaneous route is the practical advance over the intravenous original: shorter administration, less infusion-reaction risk in principle.

The label carries no boxed warning, but it lists several warnings and precautions clinicians must watch for: hypersensitivity and administration-related reactions, interstitial lung disease or pneumonitis, skin reactions, eye toxicity, and harm to a developing fetus [s1]. Interstitial lung disease in particular — inflammation and scarring of the lung tissue — is a known class effect of EGFR-directed drugs and can be serious.

What to watch

Two questions will decide how this approval ages. First, whether the confirmatory evidence shows that shrinking tumours translates into patients living longer — the gap every accelerated approval has to close. Second, how the subcutaneous formulation performs in routine use, where reaction rates and tolerability may differ from a trial population. For now, the drug gives a defined, immunotherapy- and chemotherapy-resistant group a new option, on evidence that is promising but deliberately preliminary [s1].

Red flags: new or worsening breathlessness, a persistent dry cough, fever, or a widespread rash during treatment should prompt urgent contact with the oncology team, as these can signal lung or skin reactions. This article describes regulatory news and is not medical advice. Decisions about cancer treatment are for patients and their treating clinicians.